Dr. Emmanuel Quansah is an expert in cell and molecular neurobiology, genetics and neuropharmacology with an interest in neurodegenerative disorders. He earned his B.Sc. in molecular biology and biotechnology from University of Cape Coast in Ghana followed by an M.Sc. in pharmaceutical biotechnology and a Ph.D. in molecular neurobiology from De Montfort University in the United Kingdom. His graduate work focused on the effects of the medication Ritalin (methylphenidate) on the developing brain. More recently, his work has centered on mitochondrial dysfunction and misfolded protein propagation in Parkinson’s disease, first as a research assistant under the mentorship of Dr. Nicoleta Moisoi at De Montfort University and now as a postdoctoral fellow in the laboratory of Dr. Patrik Brundin at Van Andel Research Institute. Over his academic career, Dr. Quansah has received several awards for his work, including the High-Flyers Scholarship from De Montfort and the Ghana Educational Trust Fund Scholarship from the government of Ghana.
I am currently working on novel immunotherapeutic agents directed against alpha-synuclein aggregates. This work involves validating the efficacy and safety profiles of some identified immunotherapeutic agents geared at minimizing the “prion-like” spread of pathogenic alpha-synuclein strains in models of Parkinson’s disease.
Ph.D. in molecular biology, De Montfort University (Advisor: Dr. Tyra S. C. Zetterström)
Thesis: Molecular and neurochemical effects of methylphenidate (Ritalin) on the developing brain
M.Sc. in pharmaceutical technology (graduated with distinction, Government of Ghana scholarship), De Montfort University
B.Sc. in molecular biology and biotechnology (second class upper honors), University of Cape Coast
To view a list of selected publications click below.
Chatterjee D, Sanchez DS, Quansah E, Rey NL, George S, Becker K, Madaj Z, Steiner JA, Ma J, Escobar Galvis ML, Kordower JH, Brundin P. 2019. Loss of one engrailed1 allele enhances induced alpha-synucleinopathy. J Parkinsons Dis 9(2):315–326.
Quansah E, Rodado VR, Grootveld M, Zetterström TSC. In press. Methylphenidate alters monoaminergic and metabolic pathways in the cerebellum of adolescent rats. Eur Neuropsychopharmacol.
Quansah E*, Peelaerts W*, Langston JW, Simon DK, Colca J, Brundin P. 2018. Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. Mol Neurodegener 13:28.
Quansah E, Rodado VR, Probert F, Grootveld M, Zetterström TSC. 2017. 1H NMR-based metabolomics reveals neurochemical alterations in the brain of rats treated with methylphenidate. Neurochem Int 108:109–120.
Quansah E, MacGregor NW. 2017. Towards diversity in genomics: The emergence of neurogenomics in Africa? Genomics 10.1016/j.ygeno.2017.07.009.
Quansah E, Karikari TK. 2016. Potential role of metabolomics in the improvement of research on traditional African medicine. Phytochem Lett 17:270–277.
Quansah E, Karikari TK. 2015. Motor neuron diseases in sub-Saharan Africa: The need for more population-based studies. BioMed Res Int e298409.
Quansah E, Karikari TK. 2015. Neuroscience-related research in Ghana: a systematic evaluation of direction and capacity. Metab Brain Dis 31(1):11–24.
Quansah E, Sarpong E, Karikari TK. 2015. Disregard of neurological impairments associated with neglected tropical diseases in Africa. eNeurologicalSci 3:11–14.
Karikari TK, Quansah E, Mohamed WMY. 2015. Developing expertise in bioinformatics for biomedical research in Africa. Appl Transl Genom 6:31–34.